Mammogen develops diagnostic tools and treatment protocols for breast cancer using proprietary algorithms and imaging technologies to enhance early detection and personalized care. The company targets late-stage diagnosis and ineffective treatment options, aiming to improve patient outcomes through precise interventions.
Funding
$25K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current breast cancer screening methods, like mammograms, have limitations in detecting early-stage cancers, particularly in women with dense breast tissue, leading to potential false negatives and delayed diagnoses. Supplemental screenings like ultrasounds and MRIs can increase detection rates but often result in more false positives and unnecessary biopsies, adding cost and stress for patients.
Solution
Mammogen is developing genTRU-breast, a blood test designed for the early detection of breast cancer, regardless of breast density or stage. This mRNA-based technology measures changes in gene expression patterns in blood samples to accurately identify the presence or absence of breast cancer. The test aims to provide a non-invasive, reliable screening option that reduces false negatives and false positives, enabling earlier intervention and improved patient outcomes. Mammogen's technology is positioned to offer regular and reliable screening, especially for women underserved by current standards of care, and to eliminate many unnecessary invasive biopsy procedures.
Target Audience
The primary target audience includes women undergoing routine breast cancer screening, particularly those with dense breast tissue, a family history of breast cancer, or genetic predispositions, as well as healthcare providers seeking more accurate and less invasive diagnostic tools.
Features
- Non-invasive breast cancer detection using a simple blood test
- mRNA technology that measures changes in RNA gene expression patterns
- High sensitivity and specificity (>90%) in detecting breast cancer, regardless of stage, age, or breast density
- Ability to detect common types of breast cancer, including familial, DCIS, IDC, and inflammatory breast cancer, across a range of stages (including stage 0-I)
- Designed to reduce false negatives and false positives compared to traditional screening methods
- Potential to eliminate unnecessary and invasive biopsy procedures
- Can be used as an early detection test (B-EDT) or a post-imaging diagnostic (B-PID)